The subsequent FDA-approved ISH assays introduced the dual-color chromogenic visualization that enabled HER2/CEN17 ratio determination by brightfield microscopy (Table 3) with excellent agreement to the comparator assays for HER2 status in breast cancer (55, 56). This evidence concerns the gene ERBB2 and breast carcinoma.